Adverum Biotechnologies says IND active for macular degeneration med

Adverum Biotechnologies announced its Investigational New Drug application is active for the planned multi-center, open-label, Phase 1, dose-escalation study of ADVM-022, a novel gene therapy candidate for the treatment of wet age-related macular degeneration. “We are excited to have this IND active for ADVM-022, currently the only intravitreal gene therapy candidate entering the clinic for patients with wet AMD,” said Leone Patterson, interim president and chief executive officer of Adverum Biotechnologies. “We have partnered with leading retinal specialists in the U.S. and look forward to initiating the new OPTIC clinical trial in the fourth quarter of this year.”
https://bit.ly/2NAzP0E